ABSTRACT: Nitrogen dioxide (NO\textsubscript{2}) is one of a number of nitrogen compounds that are by-products of combustion and occur in domestic environments following the use of gas or other fuels for heating and cooking. In this study, we examined the effect of two levels of NO\textsubscript{2} on symptoms, lung function and airway hyperresponsiveness (AHR) in asthmatic adults and children. In addition, in the same subjects, we examined the effects of the same levels of NO\textsubscript{2} mixed with combustion by-products from a gas space heater.

The subjects were nine adults, aged 19–65 yrs, and 11 children, aged 7–15 yrs, with diagnosed asthma which was severe enough to require daily medication. All subjects had demonstrable AHR to histamine. Exposures were for 1 h on five separate occasions, 1 week apart, to: 1) ambient air, drawn from outside the building; 2) 0.3 parts per million (ppm) NO\textsubscript{2} in ambient air; 3) 0.6 ppm NO\textsubscript{2} in ambient air; 4) ambient air + combustion by-products + NO\textsubscript{2} to give a total of 0.3 ppm; and 5) ambient air + combustion by-products + NO\textsubscript{2} to give a total of 0.6 ppm. Effects were measured as changes in lung function and symptoms during and 1 h after exposure, and in lung function and symptoms during the week following exposure.

Exposure to NO\textsubscript{2} either in ambient air or mixed with combustion by-products from a gas heater, had no significant effect on symptoms or lung function in adults or in children. There was a small, but statistically significant, increase in AHR after exposure to 0.6 ppm NO\textsubscript{2} in ambient air. However, there was no effect of 0.6 ppm NO\textsubscript{2} on AHR when the combustion by-products were included in the test atmosphere nor of 0.3 ppm NO\textsubscript{2} under either exposure condition.

We conclude that a 1 h exposure to 0.3 or 0.6 ppm NO\textsubscript{2} has no clinically important effect on the airways of asthmatic adults or children, but that 0.6 ppm may cause a slight increase in airway hyperresponsiveness. 

controlled studies of NO₂ have used direct exposures, in which the test gas is a simple NO₂/air mixture. However, gas combustion produces nitrogen oxides in the form of two species, namely nitric oxide (NO) and nitrogen dioxide (NO₂). The relative proportions of these two products varies with the design and condition of the combustion appliance. These nitrogen oxides can then further react with water to produce nitrous acid (HNO₂) and nitric acid (HNO₃). As a consequence, in indoor environments where elevated levels of NO₂ are found, a range of nitrogen compounds exist, of which NO₂ can be a major component.

The aim of the present study was to examine the effects of NO₂, at concentrations of 0.3 and 0.6 ppm, on asthmatic adults and children. In addition, in response to the ongoing discussion about the possible health effects of unflued gas heaters and their by-products, we examined the effects of the same NO₂ concentrations, but included in the test atmospheres the combustion products, including the range of oxidized nitrogen species, emitted by a domestic unflued gas space heater. We report the effects of exposure to NO₂ and other combustion by-products, on AHR, on symptoms and on lung function in adults and children with severe or moderate asthma.

Methods

Subjects

Subjects were recruited for the study through hospital out-patient clinics, by local advertising and through local schools. All subjects gave written informed consent, and for children written informed consent was given by parents. Ethics approval for the study was obtained from the Ethics Review Committee of the Central Sydney Health Service and from the NSW Department of Education for recruitment undertaken through schools.

Subjects were included in the study if they had a previous diagnosis of asthma and symptoms which required current therapy. In addition, subjects were required to have demonstrable airway hyperresponsiveness to histamine in the moderate or severe range (provocative dose of histamine causing a 20% fall in forced expiratory volume in one second (PD₂₀FEV₁) less than or equal to 1.5 µmol histamine). Subjects were required not to use household gas heating for the duration of the study.

Study design

This was a double-blind study in which the order of exposures was randomized. Subjects were exposed for 1 h on five separate occasions, 1 week apart, to ambient air alone, NO₂ and ambient air (0.3 and 0.6 ppm), and NO₂ and combustion by-products (0.3 and 0.6 ppm). The investigators responsible for the assessment of the subjects were blind to the exposure conditions. A separate team of investigators, who had no contact at all with the subjects, were responsible for setting up and monitoring the exposures. The exposures were coded and this code was broken after the data were analysed.

On each test day, after measurement of baseline lung function, subjects with forced expiratory volume in one second (FEV₁) >60% predicted had airway responsiveness to histamine measured and were then allowed to recover spontaneously, without the aid of a bronchodilator, for 1 h. After that, provided their lung function had returned to within 10% of baseline, they entered the exposure chamber. Subjects remained at rest in the chamber for 1 h. At 15 min intervals during the exposure and for the hour following exposure, peak expiratory flow rate and symptom score were recorded. One hour after the end of the exposure period, airway responsiveness was measured in all subjects with FEV₁ >60% predicted. During the week following each exposure, subjects kept a daily record of expiratory flow rates, symptoms and medication use. Airway responsiveness was measured at the end of this week. This measurement served a dual role - as an assessment of the long-term effect of the previous week's exposure and as a baseline for the new exposure undertaken that day.

Nitrogen dioxide exposure

A special "exposure room" was developed to enable exposures to known concentrations of NO₂ to be carried out. The 3.9×2.6 m exposure room was designed to reproduce as far as possible a normal home environment and included an acrylic carpet, painted walls, a wood and metal coffee table and four vinyl lounge chairs. There was a window, which was kept closed, and a controlled ventilation system. The test atmospheres were generated in an adjoining room, where NO₂ was dispersed in small aliquots from a cylinder of pure material and mixed with ambient air to obtain the required concentrations. These were conditioned to the appropriate temperature and relative humidity and then circulated to the exposure room. The concentration of nitrogen oxides in the exposure room was assessed from samples taken at various points in the room. The exposure room was evaluated to demonstrate uniformity of mixing, the performance of the NO₂ supply system and to determine the air exchange rate. Two types of exposure tests at each NO₂ concentration were undertaken. In the first, NO₂ was mixed with ambient air drawn from outside the building. In the second type of exposure, all the products derived from the operation of a gas space heater (Vulcan Quasar Flueless gas space heater, Model 8302 T18), were mixed with additional NO₂ and ambient air to match the NO₂ concentrations in the first type of exposure. For all exposures, outside air was introduced to the room at a rate of six air changes per hour.

The air inside the room and the ambient air were continuously monitored for NO₂ and NO (Monitor Laboratories Nitrogen Oxides Analyser, Model 8840). During ambient air only exposures, the NO₂ and NO concentrations were both 0.02±0.01 ppm (mean±SD). When pure NO₂ was added to the ambient air to give concentrations of 0.3±0.03 and 0.6±0.04 ppm, the respective NO concentrations were 0.09±0.02 and 0.08±0.02 ppm. Operating the gas heater, without any additional NO₂, gave room concentrations of 0.23±0.03 ppm NO₂ and 1.0±0.04 ppm NO. When these combustion products were augmented with pure NO₂, to give concentrations of 0.3±0.03 and 0.6±0.04 ppm, the respective NO concentrations were 1.0±0.03 ppm and 1.12±0.05 ppm. The concentrations
of CO and CO₂ were also measured during a subset of the test exposures. During the operation of the gas heater, CO remained below 5 ppm in all samples, and the mean CO₂ was 2022±71 ppm. The relative humidity inside the room was maintained at 55±5% and the temperature at 22±2°C for both types of exposure by using an air conditioner mounted within the air distribution system.

Symptoms and lung function during exposure

Respiratory symptoms were recorded at rest prior to exposure, and at 15 min intervals throughout the exposure and during the hour following exposure. Subjects recorded symptom scores for wheeze, shortness of breath and cough on a modified Borg scale [11] (0 = no symptoms; 10 = maximal symptoms), and the scores were summed to give a total symptom score for each 15 min interval. Peak expiratory flow rate (PEFR) was recorded at the same times using an Assess peak flow meter (HealthScan Products, NJ, USA). The best of three attempts was recorded. Peak flow rates were recorded as percentage of predicted values for adults [12] and children [13].

A Vitalograph wedge bellows spirometer (Vitalograph Ltd, Bucks, UK) was used to measure forced vital capacity (FVC) and FEV1 immediately before and 1 h after exposure. The highest of two values for FEV1 repeatable to within 100 mL was recorded. FVC and FEV1 are shown as a percentage of predicted values for adults [14] and children [15].

Airway responsiveness

Airway responsiveness was assessed using histamine inhalation tests performed according to the method of Yan et al. [16]. Briefly, histamine was administered to the subject via a handheld DeVilbiss No. 45 plastic nebulizer, in doubling doses ranging 0.03–7.8 µmol, until the FEV1 fell by 20% or more. A dose response curve was plotted and from this curve the dose causing a 20% fall in FEV1 (PD20 FEV1) was read by interpolation. All aerosol medication was withheld for 6 h and theophylline for 12 h prior to testing.

Asthma severity in the week following exposure

During the week following each exposure, the following information was recorded daily by all subjects.

Peak expiratory flow rate. Expiratory flow rate was measured, using an Assess peak flow meter, in the morning and at night, before and after bronchodilator, if used. Morning peak flow, before bronchodilator, was recorded as percentage of the highest value measured during the 5 week study (recent best). Mean morning prebronchodilator PEF, as percentage recent best, was calculated for each subject for each week [17] and used to calculate a PEF score (table 1).

Symptom scores. Symptom scores for wheeze, cough and shortness of breath were recorded daily using the following scoring system: 0 = no symptoms; 1 = occasional symptoms which do not interfere with normal activity and do not require extra medication; 2 = symptoms which do not interfere with normal activity, provided extra medication is taken; 3 = symptoms which interfere with normal activity despite extra medication; and 4 = symptoms which make normal activity impossible. The highest score for any symptom on any day was taken as the score for that day. The frequency and severity of daily symptom scores during the week was used to calculate a weekly symptom score (table 1).

Treatment. The names and doses of all medications taken each day were recorded. The number of occasions on which medication requirements increased was counted and a score given for each week (table 1). A composite asthma severity score was calculated from the diary card data. Each component of the score (PEF, as percentage recent best, symptoms and increases in medication use) contributed up to four points to a maximum composite score of 12 (table 1).

Data analysis

Effects on airway hyperresponsiveness. To determine the effect of NO2 on airway hyperresponsiveness, the difference between PD20 FEV1 values from the histamine challenge performed 1 h prior to the exposure test and the challenge performed 1 h after the exposure was calculated and expressed in terms of doubling doses. The differences for all exposures were compared by analysis of variance (ANOVA) for repeated measures. A similar analysis was performed, comparing PD20 FEV1 values from the pre-exposure challenge with those from the challenge test 1 week after exposure, to examine effects on AHR over the week following each exposure.

Table 1. – Asthma severity score

<table>
<thead>
<tr>
<th></th>
<th>0</th>
<th>1</th>
<th>2</th>
<th>3</th>
<th>4</th>
</tr>
</thead>
<tbody>
<tr>
<td>Symptoms score frequency and severity</td>
<td>None</td>
<td>1 on 3 days or less</td>
<td>1 on ≥4 days or 2 on ≤2 days</td>
<td>2 on ≥3 days or 3 on ≤2 days</td>
<td>3 on ≥3 days or 4 on any day</td>
</tr>
<tr>
<td>Increased medication change from usual</td>
<td>No change</td>
<td>BD/SCG on 1–3 days</td>
<td>BD/SCG on ≥4 days</td>
<td>Steroid aerosol 1 or more days</td>
<td>Oral steroid 1 or more days</td>
</tr>
<tr>
<td>pre-BD PEF a.m. % recent best</td>
<td>&gt;93</td>
<td>85–93</td>
<td>78–85</td>
<td>70–77</td>
<td>&lt;70</td>
</tr>
</tbody>
</table>

BD: bronchodilator; SCG: sodium cromoglycate; PEF: peak expiratory flow.
Effects on symptoms and lung function. The immediate effects of NO₂ were determined by examining changes in symptoms and lung function during and immediately after the exposure period. For each subject, the changes from baseline in symptom score, for the sum of the three symptoms, and for PEF, as a percentage of baseline value, were calculated. Mean changes for the group at each measurement point were plotted against time. For each subject, the change in PEF and symptoms score during and after each exposure was summarized as mean change and as maximum change. The differences between exposures were determined by repeated measures ANOVA and paired t-test.

Effects on severity of asthma. The effects of NO₂ on the severity of asthma were examined in the week following each exposure. The mean composite asthma severity score and mean morning peak flow were calculated for the week following each exposure and the values compared by ANOVA for repeated measures. The distribution of asthma severity scores after the room air exposure did not differ significantly from normal (Shapiro–Wilk statistic = 0.96; p=0.58).

Results

Twenty three subjects agreed to participate, of whom 20 (9 adults and 11 children) completed the study. Their details are shown in table 2. Three adult subjects withdrew: one due to worsening asthma, unrelated to the study procedures; one due to an improvement in asthma severity, so that he no longer met the inclusion criteria; and the third because of personal reasons. Of the subjects who completed the study, all were atopic, one adult had smoked cigarettes in the past, the rest were lifelong nonsmokers. All subjects were using one or more bronchodilating aerosols or dry powder inhalers, and most were taking inhaled corticosteroids. Four subjects had had previous short courses of oral corticosteroids, and kept a supply at home for use if required. None of the subjects were taking regular oral corticosteroids at the time of this study.

Baseline lung function, prior to each histamine challenge or NO₂ exposure, did not vary significantly throughout the study. Table 3 shows mean (95% confidence interval) in parenthesis.

Table 2. – Details of subjects at entry into study

<table>
<thead>
<tr>
<th>Subject No.</th>
<th>Sex</th>
<th>Age (yrs)</th>
<th>Height (cm)</th>
<th>FEV1 % pred</th>
<th>FVC % pred</th>
<th>PD₂₀FEV₁ (µmol)</th>
<th>Current treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adults</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>F</td>
<td>24</td>
<td>166</td>
<td>78</td>
<td>82</td>
<td>0.15</td>
<td>S</td>
</tr>
<tr>
<td>2</td>
<td>F</td>
<td>40</td>
<td>167</td>
<td>99</td>
<td>105</td>
<td>0.29</td>
<td>S, BDP</td>
</tr>
<tr>
<td>4</td>
<td>M</td>
<td>65</td>
<td>161</td>
<td>100</td>
<td>96</td>
<td>1.2</td>
<td>S, BDP</td>
</tr>
<tr>
<td>6</td>
<td>M</td>
<td>65</td>
<td>180</td>
<td>68</td>
<td>84</td>
<td>0.3</td>
<td>S, BDP</td>
</tr>
<tr>
<td>8</td>
<td>F</td>
<td>19</td>
<td>169</td>
<td>66</td>
<td>80</td>
<td>0.06</td>
<td>S, BDP</td>
</tr>
<tr>
<td>9</td>
<td>F</td>
<td>33</td>
<td>161</td>
<td>92</td>
<td>92</td>
<td>0.64</td>
<td>T, B</td>
</tr>
<tr>
<td>11</td>
<td>F</td>
<td>27</td>
<td>160</td>
<td>76</td>
<td>76</td>
<td>0.25</td>
<td>S, BDP, TL</td>
</tr>
<tr>
<td>18</td>
<td>F</td>
<td>21</td>
<td>168</td>
<td>73</td>
<td>91</td>
<td>0.18</td>
<td>S, B</td>
</tr>
<tr>
<td>22</td>
<td>F</td>
<td>34</td>
<td>158</td>
<td>84</td>
<td>109</td>
<td>0.2</td>
<td>S, BDP, SC</td>
</tr>
<tr>
<td>Children</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>F</td>
<td>12</td>
<td>146</td>
<td>68</td>
<td>70</td>
<td>0.33</td>
<td>S, BDP</td>
</tr>
<tr>
<td>7</td>
<td>F</td>
<td>14</td>
<td>154</td>
<td>104</td>
<td>113</td>
<td>1.26</td>
<td>S, IP, SC</td>
</tr>
<tr>
<td>13</td>
<td>M</td>
<td>13</td>
<td>162</td>
<td>59</td>
<td>72</td>
<td>0.39</td>
<td>S, SC</td>
</tr>
<tr>
<td>14</td>
<td>M</td>
<td>14</td>
<td>150</td>
<td>79</td>
<td>100</td>
<td>0.72</td>
<td>S, BDP, SC</td>
</tr>
<tr>
<td>15</td>
<td>F</td>
<td>15</td>
<td>164</td>
<td>105</td>
<td>112</td>
<td>0.21</td>
<td>S</td>
</tr>
<tr>
<td>16</td>
<td>M</td>
<td>12</td>
<td>148</td>
<td>63</td>
<td>79</td>
<td>0.13</td>
<td>S</td>
</tr>
<tr>
<td>17</td>
<td>F</td>
<td>10</td>
<td>142</td>
<td>91</td>
<td>113</td>
<td>1.14</td>
<td>S, BDP, SC</td>
</tr>
<tr>
<td>19</td>
<td>M</td>
<td>7</td>
<td>128</td>
<td>85</td>
<td>98</td>
<td>0.49</td>
<td>S, BDP</td>
</tr>
<tr>
<td>20</td>
<td>F</td>
<td>14</td>
<td>152</td>
<td>84</td>
<td>106</td>
<td>0.24</td>
<td>T, SC, B</td>
</tr>
<tr>
<td>24</td>
<td>M</td>
<td>9</td>
<td>131</td>
<td>114</td>
<td>110</td>
<td>1.5</td>
<td>T, B</td>
</tr>
<tr>
<td>25</td>
<td>M</td>
<td>8</td>
<td>128</td>
<td>118</td>
<td>111</td>
<td>1.5</td>
<td>T, SC, B</td>
</tr>
</tbody>
</table>

M: male; F: female; FEV₁: forced expiratory volume in one second; FVC: forced vital capacity; % pred: percentage of predicted value; PD₂₀FEV₁: provocative dose of histamine causing a 20% fall in FEV₁; S: salbutamol; SC: sodium cromoglycate; B: budesonide; TL: theophylline; T: terbutaline; BDP: beclometasone dipropionate; IP: ipratropium bromide.

Table 3. – FEV₁, as percentage predicted, measured immediately before each NO₂ exposure and before the histamine challenges performed 1 h before and 1 h after each exposure

<table>
<thead>
<tr>
<th>NO₂ Environment</th>
<th>1 h before NO₂</th>
<th>Immediately before NO₂</th>
<th>1 h after NO₂</th>
</tr>
</thead>
<tbody>
<tr>
<td>Room air</td>
<td>87.2 (6.9)</td>
<td>86.3 (7.3)</td>
<td>86.3 (7.5)</td>
</tr>
<tr>
<td>0.3 ppm/RA*</td>
<td>87.7 (7.5)</td>
<td>85.1 (6.4)</td>
<td>86.5 (7.5)</td>
</tr>
<tr>
<td>0.6 ppm/RA*</td>
<td>87.7 (8.3)</td>
<td>83.1 (8.4)</td>
<td>83.1 (9.5)</td>
</tr>
<tr>
<td>0.3 ppm/GH*</td>
<td>85.4 (7.7)</td>
<td>83.6 (7.1)</td>
<td>85.1 (8.4)</td>
</tr>
<tr>
<td>0.6 ppm/GH*</td>
<td>83.8 (7.8)</td>
<td>82.5 (7.6)</td>
<td>84.3 (7.7)</td>
</tr>
</tbody>
</table>

Values are presented as mean and 95% confidence interval in parenthesis. *: NO₂ plus room air (RA); #: NO₂ plus combustion by-products from gas heater (GH). FEV₁: forced expiratory volume in one second; % pred: percentage of predicted value.
Effects of NO₂ in room air on airway hyperresponsiveness. The effect of NO₂ on airway hyperresponsiveness was determined by examining changes in PD₂₀FEV₁ from the histamine challenge performed 1 h prior to the exposure and the challenge performed 1 h after the exposure. The changes in PD₂₀FEV₁ values (as mean and 95% CI of the difference between the two PD₂₀FEV₁ values) are shown separately for adults and children in table 4 and as combined data in figure 1. A positive value indicates an improvement in AHR after exposure and a negative value indicates a worsening in AHR. There were no significant differences between adults and children.

Changes in PD₂₀FEV₁ after exposure differed between the three exposure days (p<0.02). The mean difference in postexposure change in PD₂₀FEV₁ between room air and 0.6 ppm was 0.92 (95% CI 0.28–1.56) doubling doses (p=0.006). The other pairwise comparisons were not significant (room air vs 0.3 ppm: 0.40 (-0.09–0.9) doubling doses; 0.3 vs 0.6 ppm: 0.52 (-0.11–1.15) doubling doses; p=0.10). There was no significant correlation between change in PD₂₀FEV₁ after 0.6 ppm NO₂ and the baseline PD₂₀FEV₁ value (r = -0.38; df 16).

Effects of NO₂ in room air on symptoms and peak expiratory flow. The acute effects of NO₂ were determined by examining changes in symptoms and PEF from the baseline measured immediately prior to entering the chamber, during and for 1 h after the exposure period. Prior to the room air exposure, mean (±95% CI) symptom scores and PEF % pred, values were 0.75±0.82 and 85.0±6.7%, respectively, in adults, and 0.23±0.20 and 93.0±10.6%, respectively, in children. Mean changes in

Table 4. – Effects of NO₂ in 9 adults and 11 children

<table>
<thead>
<tr>
<th></th>
<th>Room air</th>
<th>0.3 ppm NO₂+RA</th>
<th>0.6 ppm NO₂+GH</th>
<th>0.3 ppm NO₂+RA</th>
<th>0.6 ppm NO₂+GH</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Adult</td>
<td>Child</td>
<td>Adult</td>
<td>Child</td>
<td>Adult</td>
</tr>
<tr>
<td>ΔAHR DD</td>
<td>0.44 (0.51)</td>
<td>0.39 (0.48)</td>
<td>-0.40 (0.61)</td>
<td>-0.61 (0.73)</td>
<td>-0.12 (1.1)</td>
</tr>
<tr>
<td>ΔPEF %</td>
<td>Adult</td>
<td>3.5 (4.3)</td>
<td>5.4 (6.5)</td>
<td>1.5 (4.2)</td>
<td>4.4 (3.3)</td>
</tr>
<tr>
<td></td>
<td>Child</td>
<td>-0.11 (3.4)</td>
<td>1.5 (4.2)</td>
<td>4.4 (3.3)</td>
<td>4.4 (3.3)</td>
</tr>
<tr>
<td>ΔSymptom score</td>
<td>Adult</td>
<td>-0.06 (0.5)</td>
<td>0.39 (0.59)</td>
<td>-0.56 (1.2)</td>
<td>-0.30 (0.43)</td>
</tr>
<tr>
<td></td>
<td>Child</td>
<td>-0.35 (0.5)</td>
<td>-0.71 (0.74)</td>
<td>-0.30 (0.43)</td>
<td>-0.23 (0.5)</td>
</tr>
<tr>
<td>During the week following each exposure</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Severity score</td>
<td>Adult</td>
<td>4.38 (1.5)</td>
<td>4.78 (1.6)</td>
<td>4.11 (0.9)</td>
<td>4.56 (1.5)</td>
</tr>
<tr>
<td></td>
<td>Child</td>
<td>4.20 (1.3)</td>
<td>4.00 (1.0)</td>
<td>5.70 (2.1)</td>
<td>4.45 (1.3)</td>
</tr>
<tr>
<td>PEF % best</td>
<td>Adult</td>
<td>80.8 (4.1)</td>
<td>80.6 (5.1)</td>
<td>80.1 (4.5)</td>
<td>80.1 (5.0)</td>
</tr>
<tr>
<td></td>
<td>Child</td>
<td>79.8 (5.1)</td>
<td>81.6 (4.5)</td>
<td>78.0 (6.7)</td>
<td>81.8 (4.1)</td>
</tr>
</tbody>
</table>

Values are presented as mean, and 95% confidence interval in parenthesis. ΔAHR: difference in airway hyperresponsiveness (doubling dose (DD) change in PD₂₀FEV₁); ΔPEF: difference in peak expiratory flow during and 1 h after exposure, as percentage change from immediately before exposure; ΔSymptom score: difference in summed Borg scores between values immediately before exposure and those during and 1 h after exposure. Asthma severity score and PEF (as percentage of recent best) were calculated from diary cards during the week following each exposure. For definitions see legend to table 2. NO₂ plus room air (RA); NO₂ plus combustion by-products from gas heater (GH).

PEF and symptom scores from baseline, for each exposure, in adults and children are shown in table 4. Mean changes in symptom scores and PEF values did not differ significantly from zero and there were no significant differences between adults and children. There were no significant differences between the three exposure days in PEF, expressed as either the average change (p=0.46) or the maximum change (p=0.51), or in symptom score, expressed as either average change (p=0.42) or maximum change (p=0.29). Figure 2 shows mean changes in PEF, as percentage fall during and 1 h after exposure to room air and 0.6 ppm NO₂.

Fig. 1. – Change in airway hyperresponsiveness (AHR) from baseline to 1 h after exposure, shown as mean and 95% confidence intervals of the doubling dose difference between the two PD₂₀FEV₁ values. Data for adults and children are combined. The solid line at zero indicates no change. A positive value indicates improved AHR after exposure and a negative value indicates a worsening in AHR. PD₂₀FEV₁: provocative dose of histamine causing a 20% fall in forced expiratory volume in one second; GH: plus combustion by-products from gas heater.
Effects of NO\textsubscript{2} in room air on severity of asthma. The effects of NO\textsubscript{2} on the severity of asthma were examined in the week following each exposure. The asthma severity score, which was calculated from the diary card data, was not significantly different following any of the active exposures from that following room air. Figure 3 shows the mean (95% CI) differences between the scores following room air and those following each of the active exposures. Table 4 shows mean asthma severity scores and mean morning peak flow, as percentage of recent best, after each exposure in adults and children.

There were no effects on AHR a week after any of the exposures. Figure 4 shows changes in AHR, as the doubling dose difference between PD\textsubscript{20}FEV\textsubscript{1} values, from baseline to one week after exposure.

Effects of NO\textsubscript{2} plus combustion by-products. Addition to the test atmospheres of the combustion by-products from the gas heater had no effect on any of the lung function variables described above. Changes in AHR in the exposures which included the gas heater outputs are shown in figures 1 and 4. Repeated measures ANOVA showed that the effect of the addition of the combustion by-products differed between the two levels of NO\textsubscript{2} exposure (p=0.01). At 0.3 ppm, the heater caused a 0.14 (95% CI 0.22–0.51) relative increase in PD\textsubscript{20}FEV\textsubscript{1}, whereas at 0.6 ppm the heater caused a 0.86 (0.25–1.49) relative decrease in PD\textsubscript{20}FEV\textsubscript{1}. The slight worsening of AHR which was found after 0.6 ppm NO\textsubscript{2} in room air was not found in the presence of the gas heater by-products. Figure 5 compares the changes in PEF, as percentage change from baseline, with and without the gas heater output during exposures to 0.3 ppm NO\textsubscript{2} (fig. 5a) and 0.6 ppm NO\textsubscript{2} (fig. 5b). During exposure to 0.6 ppm NO\textsubscript{2}, PEF values were higher in the presence of the gas heater (mean difference in PEF, percentage change from baseline, 8.02±7.0%; p=0.03). The gas heater did not influence the response to 0.3 ppm NO\textsubscript{2} (mean difference in PEF, percentage change from baseline, 1.6±3.5%; p=0.35).

Discussion

In this study, a 1 h exposure to nitrogen dioxide, at either 0.3 or 0.6 ppm had no effect on peak expiratory flow or symptoms in asthmatic subjects. There was a small increase in airway hyperresponsiveness (AHR) 1 h after exposure to 0.6 ppm NO\textsubscript{2} but this increase was not present when combustion by-products from a gas heater were included in the test atmosphere. There was no effect of 0.3 ppm NO\textsubscript{2}.

In order to establish safe levels for NO\textsubscript{2} for the community as a whole, it is essential to consider its effects on those most at risk. In this study, we examined the effect of realistic exposure situations in people with relatively severe asthma, with AHR in the moderate to severe range. Asthma of this severity is found in approximately 3% of the Australian population [18, 19]. The subjects in this study were reasonably representative of this population of asthmatics, in that all required daily treatment, and most were taking inhaled corticosteroids. It is
suggested that children may be more susceptible to NO2 and children differed, although previous studies have
denced in the present study that the responses of adults
ing during this period, but the four subjects who had gas
from November 1992 to May 1993. Subjects were un-

There was no correla-
tion between severity of baseline AHR and the change
in AHR after exposure to 0.6 ppm NO2, suggesting that
subjects with more severe AHR do not have increased
susceptibility to the effects of NO2. There was no evi-
dence in the present study that the responses of adults
and children differed, although previous studies have
suggested that children may be more susceptible to NO2
[8].

The study was carried out in the warm summer months,
from November 1992 to May 1993. Subjects were un-
likely to have been exposed to any type of domestic heat-
ing during this period, but the four subjects who had gas
heaters installed at home were instructed not to use them
for the duration of the study. We could not control for
use of gas cookers. However, exposure to gas from cook-
ers is likely to have occurred randomly throughout the
study, and thus have no systematic effect on the results.
Most subjects were atopic to house dust mites, which are
at high levels year round in Sydney, so the findings are
unlikely to be confounded by any seasonal effects.

A number of studies have shown that exposure to NO2,
in the range 0.1–0.5 ppm, may cause an increase in AHR
in asthmatic subjects [9, 20–24]. However, some of these
positive findings have come from studies with dubious statistical analyses [9, 22], and other studies in the same
concentration range have not reproduced the findings
[25, 26]. A recent meta-analysis of 25 controlled clini-
cal trials suggested that AHR increases in asthmatic sub-
jects after exposure to concentrations of NO2 below 1.0
ppm and also in normal subjects after exposure to con-
centrations above 1.0 ppm [27]. In the present study,
there appeared to be a small increase in AHR after expo-
sure to 0.6 ppm NO2. However, the increase was due to
a change of only half a doubling dose in PD20FEV1,
from a mean of 0.42 to 0.32 µmol. In previous studies
which have shown increases in AHR, where it is possi-
ble to estimate the size of the change from the published
data, changes have ranged from a half [22] to one dou-
bling dose or concentration [9, 20]. The clinical rele-
vance of such changes is uncertain, since they are close
to the limits of reproducibility of most tests of AHR.

This may be especially true in the present study, when
exposure to 0.6 ppm NO2, including the by-products from
the gas heater, had no effect on AHR.

In this study, we controlled for the day to day vari-
ability in AHR by doing two histamine challenges on
the same day, 1 h before and 1 h after the NO2 expo-
sure. From figure 1 it can be seen that there was a small
but significant decrease in AHR after room air exposure,
suggesting that there may be a slight tachyphylaxis.
Changes in AHR have been analysed both as absolute
change from the daily baseline and as a comparison with
changes during the room air control exposure. Only the
0.6 ppm exposure caused a change in AHR which dif-
fered significantly from that after the room air control.
There were no significant differences in baseline lung
function between study days or, more importantly, be-
 tween the pre- and postexposure histamine challenges.
However, although not statistically significant, on the 0.6
ppm/room air exposure day, baseline lung function 1 h
before and 1 h after exposure differed by approxima-
tely 4.6%. This was due, in part, to the two subjects whose
lung function postexposure was too low to allow a his-
tamine challenge. However, there was no significant cor-
relation (r=0.28) between the change in baseline lung
function and change in AHR.

If exposure to NO2 caused inflammatory changes in
the airways, it is likely that such an exposure would be
accompanied by an increase in the severity of asthma
during the days immediately following the exposure. In
the present study, one child suffered an attack of asth-
ma on the night following 0.6 ppm NO2. We were unable
to measure her airway hyperresponsiveness on the day
of this exposure due to her poor lung function. This child
had severe asthma and had had several attacks requiring
treatment with short courses of oral steroids during the
previous year. It is not clear if this attack was related to
the NO2 exposure, but she had no untoward effects after

Fig. 5. – Mean (95% confidence interval) changes in peak expira-
tory flow (ΔPEF), as percentage fall from baseline, during exposures
to: a) 0.3 ppm NO2; and b) 0.6 ppm NO2, mixed with room air (RA)
or with the output of the gas heater (GH). The line at zero indicates
no change. – – : NO2 + room air; – – – : NO2 + output of gas
heater.
0.6 ppm NO₂ mixed with the combustion by-products. In the rest of the group, there were no significant changes in the severity of asthma, assessed as symptoms, medication use or lung function, in the days following exposure. The use of a composite asthma score to analyse the diary card data has allowed us to compensate for changes in symptoms or lung function associated with changes in medication, which may be missed when the components are analysed separately.

In this study, exposure to NO₂ did not induce any acute asthmatic responses, as evidenced by the symptom scores and PEF measurements recorded during and for 1 h after each exposure. The largest mean fall in PEF was 3 ±(4.1)% during the 0.6 ppm NO₂ exposure, which was not statistically significant. Detection of smaller lung function changes would require larger sample sizes or more sensitive lung function tests. Evidence from previous controlled exposures suggests that NO₂ has little effect on lung function, even in susceptible populations of asthmatic subjects. Controlled exposures to NO₂, in concentrations ranging from 0.1 ppm [24] to 4 ppm [10] have shown little or no direct effect on expiratory flow rates or on more sensitive tests, such as airway resistance.

Oxides of nitrogen which are produced in normal indoor environments are complex chemical mixtures which interact with their environment. There are potential interactions between the components of the complex mixtures, which may modify their effects on the respiratory system. Many previous studies of the effects of NO₂ have used highly controlled exposure methods, using direct exposures through a mouthpiece [28, 29] or environmental chambers [20, 23, 26, 30]. While such studies help to isolate and identify important effects of pollutants, they bear little relationship to real world exposures. The present study attempted to mimic real life exposures in two ways: 1) the nature of the exposure chamber; and 2) increasing the complexity of the test atmospheres by including combustion by-products from an unflued gas heater. The exposure chamber contained surfaces and furnishings which resembled the environment in which people are most likely to be exposed. Whilst it is likely that the test gases interacted with this environment, there was sufficient throughput of air to ensure that the NO₂ content was maintained at the appropriate level. Inclusion of the combustion by-products in the test atmospheres produced levels of nitric oxide (NO) of 1.1 ppm. This is a relatively low concentration, but at higher concentrations NO might be expected to cause some bronchodilation [31]. It is possible that an adverse effect of NO₂ may be counteracted by the coincident presence of NO. The results of this study clearly show that the inclusion of combustion by-products in the test atmospheres does not magnify the effect of NO₂ on respiratory function.

The present study has shown that isolated hour long exposures to 0.3 and 0.6 ppm NO₂ did not produce adverse effects in these asthmatic subjects. However, the effects of prolonged exposures to lower levels have not been examined. Two recent studies [32, 33] have suggested that response to allergen may be enhanced by prior exposure to NO₂. Because the duration of exposures to NO₂ in schools and in homes during the winter heating period is likely to be greater than the one hour exposure examined here, and because exposure is likely to occur in the presence of allergen, further studies are required to examine the effect of chronic low level exposures in domestic environments on the respiratory health of asthmatic subjects.

Acknowledgements: The authors wish to acknowledge the financial support of the National Health and Medical Research Council, the technical support of T. Treu and L. Trevillion, the editorial and statistical advice of J. Peat and the enthusiasm of their asthmatic subjects.

References

16. Yan K, Salome C, Woolcock A. Rapid method for the


